TrialRHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
Trial details
- Registry ID
- NCT04616924
- Phase
- Phase 3
Drug research
RHB-204
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Clarithromycin 158.3mg, Rifabutin 40mg and Clofazimine 13.3mg
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex DiseaseNCT04616924 | RedHill Biopharma Limited | Phase 3 | Terminated | 2023-08-28Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |